GRAIL, Inc.
NASDAQ:GRAL · NASDAQ Global Market
+$1.90 today
Vol 0.89M · Avg 0.77M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-15.8%
avg -51.6%
ROIC
-14.3%
avg -46.2%
ROA
-14.0%
avg -43.3%
Analysis
ROA is currently the strongest return metric at -14.0% versus its period average of -43.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert Ragusa | Advisor | $1.62M | — | 66 | $518,582.00 | 1.21% |
Aaron Freidin | Chief Financial Officer | $1.13M | — | 47 | $260,669.00 | 0.61% |
Joshua J. Ofman | CEO, President & Director | $1.12M | — | 61 | $402,271.00 | 0.94% |
Paul Ciccolella | Senior Vice President of Global Development & Operations | — | — | — | — | — |
Alison Highlander | Senior Vice President of Human Resources & Head of People Team | — | — | — | — | — |
Erin Polak | Senior Vice President of Government Affairs, Policy, and Alliance Development | — | — | — | — | — |
Linda J. Peters | Senior Vice President of Quality & Regulatory | — | — | 48 | $402,271.00 | 0.94% |
Sir Harpal S. Kumar | Chief Scientific Officer & President International | — | — | — | — | — |
Alexis Tosti | Vice President of Strategy & Corporate Development | — | — | — | — | — |
Eric T. Fung | Senior Vice President of Clinical Development | — | — | 56 | — | — |
Abram Barth | Chief Legal Officer & Corporate Secretary | — | — | — | — | — |
Andrew John Partridge | Chief Commercial Officer | — | — | 57 | $163,738.00 | 0.38% |
Satnam Alag | Senior Vice President of Software Engineering & Chief Security Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
39
$128.34M
Net Sentiment
$128.34M
Net selling
Most Active
Ofman Joshua J.
13 transactions
1–10 of 39
Analysis
Insiders reported 0 buys worth $0.00 and 39 sells worth $128.34M over the last 12 months. That adds up to net selling of $128.34M. Ofman Joshua J. was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | +31.4% (8yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Forward estimates point to Revenue at +31.4% (8yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.17B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.45B
Celcuity Inc.
NASDAQ:CELC
$4.19B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.18B
Envista Holdings Corp
NYSE:NVST
$4.15B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.23B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.92B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.74B
Ascentage Pharma Group International
NASDAQ:AAPG
$407.64M
Who manages GRAL?
GRAIL, Inc. (GRAL) lists 13 active executives. The top listed executive is Robert Ragusa, Advisor.
Are GRAL insiders buying or selling?
Recent insider activity shows net selling of $124.28M.
Explore More
Continue the stock analysis
Jump to another research area for this company.